ArticleAIDS (London, England)2019
Differences in the rate of nicotine metabolism among smokers with and without HIV.
Article in AIDS (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetics of Nicotine Addiction Treatment (PNAT)
A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS
Who cites it
39 citing papers in PubMed, 46 citations in OpenAlex.
- The Nicotine Metabolite Ratio and Response to Smoking Cessation Treatment Among People Living with HIV Who Smoke in South Africa.International journal of environmental research and public health · 2025Trial
- A Cross-Sectional Analysis of the Nicotine Metabolite Ratio and Its Association with Sociodemographic and Smoking Characteristics among People with HIV Who Smoke in South Africa.International journal of environmental research and public health · 2023Trial
- Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder.The American journal on addictions · 2021Trial
- Prediction of Smoking Abstinence in Women Living With Human Immunodeficiency Virus Infection.Nursing researchTrial
- Nicotine and neurocognition in HIV: Translational challenges and therapeutic potential.Neuroscience and biobehavioral reviews · 2025Review
- Acute nicotine vapor attenuates sensorimotor gating deficits in HIV-1 transgenic rats.Psychopharmacology · 2025Article
- Determinants of Brain Atrophy in People Living with HIV: The Role of Lifestyle, Demographics, and Comorbidities.Journal of clinical medicine · 2025Article
- Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.Nanomedicine (London, England) · 2025Review
- HIV, smoking, and the brain: a convergence of neurotoxicities.AIDS research and therapy · 2025Review
- PharmVar GeneFocus: CYP2A6.Clinical pharmacology and therapeutics · 2024Review
- Acute nicotine vapor normalizes sensorimotor gating and reduces locomotor activity deficits in HIV-1 transgenic rats.bioRxiv : the preprint server for biology · 2024Article
- Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz-Based Therapy in People With HIV Who Smoke.Clinical pharmacology and therapeutics · 2024Article
- Human Immunodeficiency Virus as a Risk Factor for Cardiovascular Disease.Cardiovascular toxicology · 2024Review
- The impacts of tobacco and nicotine on HIV-1 infection, inflammation, and the blood-brain barrier in the central nervous system.Frontiers in pharmacology · 2024Review
- Prevalence and trends of cigarette smoking among adults with HIV infection compared with the general population in Korea.Epidemiology and health · 2024Article
- Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- The use of biomarkers to guide precision treatment for tobacco use.Addiction neuroscience · 2023Article
- Robust tobacco smoking self-report in two cohorts: pregnant women or men and women living with or without HIV.Scientific reports · 2023Article
- Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.International journal of chronic obstructive pulmonary disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveHIV-infected smokers lose more life years to tobacco use than to HIV infection. The nicotine metabolite ratio (NMR), a biomarker of CYP2A6, represents individual variation in the rate at which nicotine is metabolized and is associated with response to smoking cessation treatments. We evaluated whether HIV-infected smokers metabolize nicotine faster than HIV-uninfected smokers, which may contribute to the disproportionate smoking burden and may have important treatment implications.
designWe analysed baseline data from two clinical trials (NCT01710137; NCT01314001) to compare the NMR in HIV-infected smokers (N = 131) to HIV-uninfected smokers (N = 199).
methodsPropensity scores were used to match the groups 2 : 1 on characteristics that influence NMR: sex, race, BMI and smoking rate. Nicotine metabolites were assessed via liquid chromatography-tandem mass spectrometry methods and the ratio of 3-hydroxycotinine:cotinine was used to compute the NMR.
resultsHIV-infected smokers had significantly higher NMR (mean = 0.47, SEM = 0.02) and were more likely to be in the highest NMR quartile compared with HIV-uninfected smokers (mean = 0.34, SEM = 0.02; Ps < 0.001).
conclusionThe higher NMR observed among HIV-infected smokers may partially explain higher smoking rates and lower response to transdermal nicotine therapy. Understanding the mechanisms by which HIV and/or ART contribute to faster nicotine metabolism may guide the use of the NMR to personalize tobacco cessation strategies in this underserved population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.